Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance-Reference-Cited by-同舟云学术

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

Published:2022-11-01 Issue:11 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

De Miguel Buckley Rosa¹²^ORCID,Rial-Crestelo David²³^ORCID,Montejano Rocío¹²,Pinto Adriana³,Jimenez-Gonzalez María¹²,Lagarde Maria²³⁴,Esteban-Cantos Andrés¹²,Aranguren-Rivas Paula³,Cadiñanos Julen¹²,Bisbal Otilia²³,Castro Juan Miguel¹,Santacreu-Guerrero Mireia³,Bermejo-Plaza Laura³,Moreno Victoria¹,Hernando Asunción²³,Martín-Carbonero Luz¹²,Rubio Rafael²³⁴,Delgado Rafael⁴⁵^ORCID,Arribas José Ramón¹²⁶,Pulido Federico²³⁴^ORCID,

Affiliation:

1. Infectious Diseases Unit, La Paz University Hospital, Instituto de Investigación Hospital Universitario La Paz , Madrid , Spain

2. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas , CIBERINFEC , Spain

3. HIV Unit, University Hospital 12 de Octubre–Imas12 , Madrid , Spain

4. Universidad Complutense School of Medicine , Madrid , Spain

5. Department of Microbiology, University Hospital 12 de Octubre–Imas12 , Madrid , Spain

6. School of Medicine, Universidad Autónoma de Madrid , Madrid , Spain

Abstract

Abstract In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qualitative detection methods, irrespective of past lamivudine resistance. Clinical Trials Registration. NCT03539224.

Funder

Fondo de Investigaciones Sanitarias

Instituto de Salud Carlos III

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac610/46862035/ofac610.pdf

Reference13 articles.

1. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting;Deschanvres;J Antimicrob Chemother,2021

2. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients;Galizzi;Int J Antimicrob Agents,2020